Investigation of Endocrine Disease Frequency in Dyslipidemia

Objective: The purpose of our research was to investigate the frequency of endocrine disorders like diabetes, high blood pressure, obesity, hyperuricemia, insulin resistance, and thyroid dysfunction, all of which are thought to be critical in the process of diagnosing and treating patients who have dyslipidemia.

Methods: Between December 2010 and May 2012, a total of 200 patients with dyslipidemia and 23 healthy control groups without dyslipidemia who applied to the general internal medicine and subspecialty outpatient clinics at the Atatürk University Faculty of Medicine were included in the study. The mean age of the dyslipidemic patients was 49 ± 15 years, and the mean age of the healthy control groups was 32 ± 17 years. Anthropometric measures were obtained, as well as measurements of triglyceride levels, total cholesterol levels, low-density lipoprotein cholesterol levels, high-density lipoprotein cholesterol levels, free T4 levels, Thyroid-stimulating hormone (TSH), The hemoglobin A1c (HbA1C) levels, serum uric acid levels, fasting insulin levels, fasting blood glucose levels and Hemoglobin A1c (HbA1c) .

Results: It was shown that diabetes mellitus is the most common endocrine condition that occurs in conjunction with dyslipidemia, with a prevalence of 52%. While there was a statistically significant increase in HbA1c, body mass index, and uric acid values of the dyslipidemic group compared to the control group (P < .05), no difference was found between the 2 groups in TSH and homeostasis model assessment index-insulin resistance (HOMA-IR) values. Also, 85 of the patients in the dyslipidemic group (42.5%) were found to have systemic hypertension, but only one of the patients in the control group (4.3%) had hypertension (p < .001).

Conclusion: The frequency of diabetes, hypertension, obesity, and hyperuricemia in patients with dyslipidemia was significantly higher than in the control group. Considering these diseases when treating dyslipidemia is important for cardiovascular morbidity and mortality.

Cite this article as: Aslan V, Akçay G. Investigation of endocrine disease frequency in dyslipidemia. Arch Basic Clin Res., 2023;5(1):185-193.